Clinical trials: Atezolizumab
Breast Cancer
A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer
JCOG1919E (AMBITION) is a randomized, open-label, phase 3 trial to evaluate efficacy and safety of bevacizumab and paclitaxel in combination with atezolizumab comparing to bevacizumab and paclitaxel in patients with HR-positive…
- Trial name
- AMBITION (NCT04732598)
- Testing
- Paclitaxel + bevacizumab therapy, Paclitaxel + bevacizumab + atezolizumab
- Where
- Japan
- Volunteers
- 281 people
- Sponsor
- Japanese Foundation for Cancer Research
Breast Cancer, Oligometastasis
Metastasis-directed Therapy for Oligometastases of Breast Cancer
OLIGAMI trial is a multi-institutional, two-arm, open-label, randomized controlled phase III trial being conducted with the participation of 50 hospitals belonging to Japan Clinical Oncology Group.
- Conditions
- Breast Cancer, Oligometastasis, Metastatic Breast Cancer
- Trial name
- OLIGAMI (NCT06135714)
- Testing
- Systemic therapy for 12 weeks after primary registration, Radiation therapy (SBRT/conventional RT), Surgery
- Where
- Japan
- Volunteers
- 146 people
- Sponsor
- Tokyo Medical and Dental University
Lung Cancer, Non-Small Cell Lung Cancer
MPDL3280A With Chemoradiation for Lung Cancer
The goal of this clinical research study is to learn about the safety of adding MDPL3280A to standard chemotherapy (a combination of carboplatin and paclitaxel) and radiation in patients with lung cancer.
- Trial name
- NCT02525757
- Testing
- MPDL3280A, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma
This is a Phase 1 dose-exploration study of LAM-002A administered by mouth in patients with relapsed or refractory B-cell NHL. Safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD),and preliminary anti-tumor activity…
- Trial name
- LAM-002A/NHL (NCT02594384)
- Testing
- LAM-002A, Rituximab, Atezolizumab
- Where
- 11 sites in United States
- Volunteers
- 62 people
- Sponsor
- IRulya Therapeutics Inc.
Hepatocellular Carcinoma
Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma
To observe and evaluate the efficacy and safety of selective internal radiotherapy (SIRT) based on transarterial radioembolization with yttrium (90Y) microspheres combined with immune checkpoint inhibitors and…
- Trial name
- NCT06867432
- Testing
- Combination Product：t: SIRT-Y90 +HAIC+Atezolizumab + Bevacizumab
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric and Gastroesophageal Junction Carcinoma
An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced gastric carcinoma (GC) or gastroesophageal junction carcinoma (GEJC).
- Trial name
- NCT05251948
- Testing
- Atezolizumab, Capecitabine, Oxaliplatin
- Where
- 11 sites in China
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer
This is a single arm multicenter non-randomized phase II trial testing the efficacy of the combination of carboplatin plus atezolizumab in metastatic ILC
- Trial name
- GELATO (NCT03147040)
- Testing
- Carboplatin, Atezolizumab
- Where
- 4 sites in Netherlands
- Volunteers
- 23 people
- Sponsor
- The Netherlands Cancer Institute
Pancreatic Cancer
Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
The purpose of this study is to evaluate the safety or treating pancreatic cancer with surgery to remove cancerour tissue, followed by atezolizumab, followed by a personalized cancer vaccine (PCV), and then with chemotherapy.
- Trial name
- NCT04161755
- Testing
- Atezolizumab, RO7198457, mFOLFIRINOX
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Nonsmall Cell Lung Cancer, Performance Status
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
This pilot study is configured as a non-inferiority comparison of Performance Status 2 patients with Performance Status 0-1 patients, with the goal of demonstrating non-inferiority in terms of efficacy (progression-free survival…
- Trial name
- NCT04253964
- Testing
- Pembrolizumab, Atezolizumab, Cemiplimab-Rwlc
- Where
- 2 sites in United States
- Volunteers
- 105 people
- Sponsor
- Wake Forest University Health Sciences
Non Small Cell Lung Cancer, Colorectal Cancer
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT05395052
- Testing
- FT536, Cyclophosphamide, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fate Therapeutics
HER2-positive Breast Cancer
TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery
This study was phase IB-II clinical trial that designed to evaluate the efficacy and safety of docetaxel + atezolizumab + Herceptin sc plus pertuzumab(TAHP) plus adjuvant therapy of atezolizumab + trastuzumab + pertuzumab(AHP)…
- Trial name
- NCT03881878
- Testing
- TAHP and AHP, TAHP plus AC and AHP
- Where
- South Korea
- Volunteers
- 67 people
- Sponsor
- Samsung Medical Center
Non-small Cell Lung Cancer
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study will evaluate the safety and efficacy of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in chemotherapy-naive patients with locally advanced unresectable or metastatic PD-L1-selected non-small…
- Trial name
- NCT03563716
- Testing
- Atezolizumab, Tiragolumab
- Where
- 40 sites in United States, France and 4 more
- Volunteers
- 135 people
- Sponsor
- Genentech, Inc.
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with locally…
- Trial name
- NCT03281369
- Testing
- 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 219 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
There is an unmet need for patients with intermediate stage hepatocellular carcinoma (HCC). It is known that local tumor ablation can increase tumor immunogenicity by releasing tumor associated antigens, potentially increasing…
- Trial name
- NCT05776875
- Testing
- Atezolizumab Injection, Bevacizumab, Transarterial chemoembolization
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Hepatocellular Carcinoma
Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma
The study will assess the efficacy of Ezurpimtrostat in association with standard of care (Atezolizumab-Bevacizumab), compared to standard of care alone, as first line treatment in patients with unresectable hepatocellular…
- Trial name
- ABE-LIVER (NCT05448677)
- Testing
- Ezurpimtrostat, Atezolizumab, Bevacizumab
- Where
- France
- Volunteers
- 3 people
- Sponsor
- University Hospital, Grenoble
Tumor, Solid
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab
A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors
- Trial name
- EIK1001 (NCT04196530)
- Testing
- BDB001 (EIK1001), Atezolizumab
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Eikon Therapeutics
Bile Duct Cancer, Gall Bladder Cancer
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous…
- Conditions
- Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors
- Trial name
- NCT05000294
- Testing
- Atezolizumab, Tivozanib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Florida
Cancer
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary
The goal of this clinical research study is to learn if the combination of atezolizumab and tiragolumab can help to control cancers of unknown primary. The safety and effects of this drug combination will also be studied
- Trial name
- NCT06754501
- Testing
- Atezolizumab, Tiragolumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
This study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab in combination with bevacizumab, bevacizumab + oxaliplatin, leucovorin and 5-fluorouracil (5-FU) (FOLFOX), vanucizumab, nab-paclitaxel +…
- Trial name
- NCT02715531
- Testing
- 5-FU, Atezolizumab, Bevacizumab
- Where
- 30 sites in United States, Australia and 5 more
- Volunteers
- 243 people
- Sponsor
- Hoffmann-La Roche
Extensive Stage-small Cell Lung Cancer
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small…
- Trial name
- NCT06362252
- Testing
- Ifinatamab deruxtecan, Atezolizumab, Carboplatin
- Where
- 58 sites in United States, France and 2 more
- Volunteers
- 123 people
- Sponsor
- Daiichi Sankyo